Epic Corp. reported earnings results for the nine months ended June 30, 2013. For the period, the company reported net profit of $1,827,877 or $0.17 per undiluted share.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | 0.00% | 0.00% | 0.00% |
2022 | Sanofi profit gain beats market view on bestseller drug Dupixent | RE |
2022 | Sanofi to float drug ingredients manufacturing business on May 6 | RE |
1st Jan change | Capi. | |
---|---|---|
0.00% | 20 | |
+25.44% | 53.55B | |
+17.23% | 7.07B | |
-29.61% | 819M | |
+100.00% | 542M | |
+188.97% | 424M | |
-52.94% | 328M | |
-10.17% | 127M | |
-.--% | 118M | |
-13.78% | 102M |
- Stock Market
- Equities
- EPOR Stock
- News Epic Corp.
- Epic Corp. Reports Earnings Results for the Nine Months Ended June 30, 2013